Tower Research Capital LLC TRC Purchases 3,211 Shares of Haleon plc (NYSE:HLN)

Tower Research Capital LLC TRC grew its position in shares of Haleon plc (NYSE:HLN) by 146.8% in the 4th quarter, HoldingsChannel reports. The fund owned 5,398 shares of the company’s stock after buying an additional 3,211 shares during the period. Tower Research Capital LLC TRC’s holdings in Haleon were worth $44,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of HLN. Van ECK Associates Corp boosted its position in shares of Haleon by 18.7% during the third quarter. Van ECK Associates Corp now owns 2,470,295 shares of the company’s stock valued at $20,578,000 after buying an additional 389,194 shares during the last quarter. QVIDTVM Management LLC boosted its position in shares of Haleon by 36.8% during the third quarter. QVIDTVM Management LLC now owns 709,564 shares of the company’s stock valued at $5,911,000 after buying an additional 190,836 shares during the last quarter. Mariner LLC boosted its position in shares of Haleon by 32.8% during the third quarter. Mariner LLC now owns 345,866 shares of the company’s stock valued at $2,881,000 after buying an additional 85,357 shares during the last quarter. Cambiar Investors LLC purchased a new position in shares of Haleon during the fourth quarter valued at approximately $15,225,000. Finally, Oppenheimer Asset Management Inc. boosted its position in shares of Haleon by 49.5% during the third quarter. Oppenheimer Asset Management Inc. now owns 653,972 shares of the company’s stock valued at $5,448,000 after buying an additional 216,478 shares during the last quarter. Institutional investors own 6.67% of the company’s stock.

Haleon Stock Performance

HLN stock traded down $0.03 during midday trading on Thursday, hitting $8.32. The company’s stock had a trading volume of 9,937,608 shares, compared to its average volume of 5,403,693. The stock’s 50-day moving average price is $8.34 and its 200 day moving average price is $8.29. The company has a quick ratio of 0.73, a current ratio of 1.04 and a debt-to-equity ratio of 0.53. Haleon plc has a 1 year low of $7.70 and a 1 year high of $8.98. The stock has a market cap of $37.99 billion, a price-to-earnings ratio of 29.79, a PEG ratio of 2.23 and a beta of 0.28.

Haleon Announces Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Thursday, May 16th. Shareholders of record on Friday, March 15th will be given a $0.1064 dividend. The ex-dividend date of this dividend is Thursday, March 14th. This represents a yield of 1.8%. Haleon’s dividend payout ratio is currently 75.00%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on HLN. Argus reaffirmed a “buy” rating on shares of Haleon in a research report on Tuesday, March 26th. HSBC began coverage on Haleon in a research report on Wednesday, April 17th. They set a “buy” rating on the stock. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Haleon has a consensus rating of “Moderate Buy”.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.